Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity
You may also be interested in...
2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka
Astellas is on the verge of significantly increasing its heretofore small presence in oncology in the U.S. and abroad as it, along with its partners, prepares to file one and possibly two NDAs, including for the promising prostate cancer treatment MDV3100.
2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka
Astellas is on the verge of significantly increasing its heretofore small presence in oncology in the U.S. and abroad as it, along with its partners, prepares to file one and possibly two NDAs, including for the promising prostate cancer treatment MDV3100.
Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban
Unable to find a partner to co-develop the compound, Astellas is bowing out of the anticoagulant space.